---
schema_version: "secwatch.filing_event.v1"
accession: "0001104659-23-022597"
form_type: "8-K"
ticker: "IRWD"
cik: "0001446847"
company_name: "IRONWOOD PHARMACEUTICALS INC"
filed_at: "2023-02-16T23:59:59+00:00"
generated_at: "2026-06-19T09:10:10.689827+00:00"
event_type: "earnings"
sentiment: "neutral"
materiality_score: 0.75
calibrated_materiality_score: 0.75
confidence: "high"
source: SEC EDGAR
---

# Ironwood reports FY 2022 GAAP net income $175M; FDA grants priority review for LINZESS pediatric sNDA

## Summary
- FY 2022 total revenues $410.6M (down ~1% YoY); GAAP net income $175.1M vs $528.4M in FY 2021.
- Q4 2022 total revenues $107.2M; GAAP net income $48.9M ($0.27 diluted EPS).
- Adjusted EBITDA for FY 2022 was $252M, up from $234M in FY 2021; cash and equivalents $656M.
- FDA granted priority review for LINZESS sNDA for pediatric functional constipation (ages 6-17); PDUFA date Q2 2023.
- CEO cited robust prescription demand but lower LINZESS sales growth due to retail channel inventory fluctuations.

## SEC filing metadata
- accession: 0001104659-23-022597
- form_type: 8-K
- ticker: IRWD
- cik: 0001446847
- company_name: IRONWOOD PHARMACEUTICALS INC
- filed_at: 2023-02-16T23:59:59+00:00
- event_type: earnings
- sentiment: neutral
- materiality_score: 0.75
- calibrated_materiality_score: 0.75
- confidence: high
- sec_items: 2.02, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1446847/000110465923022597/0001104659-23-022597-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1446847/000110465923022597/tm236845d1_8k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001104659-23-022597
- JSON: https://secwatch.observer/filing/0001104659-23-022597.json
- Plain text: https://secwatch.observer/filing/0001104659-23-022597.txt

## Key facts
- Earnings Releases
  IRONWOOD PHARMACEUTICALS INC reported financial results for quarter and year ended December 31, 2022.
  - Period: quarter and year ended December 31, 2022
  - Result: reported results
  source text: On February 16, 2023, Ironwood Pharmaceuticals, Inc. issued a press release containing an update on its recent business activities as well as those for the quarter and year ended December 31, 2022.
  evidence_url: https://www.sec.gov/Archives/edgar/data/1446847/000110465923022597/0001104659-23-022597-index.htm

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.